CD8A and neoplasm: Type II IFN (IFN-γ) is released by CD8+ T and Th1 cells, activating cells, such as NK cells, M1-type macrophages and cytotoxic CD8+ T cells, increasing MHC I and II presentation, thus enhancing anti-tumor immunity [25].